profit from every $100 of sales.
$0$100
MAIA Biotechnology
$1.03-1.90% today
-8.0% in 1 year
1-year low $0.871-year high $2.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What MAIA Biotechnology sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$22.4 million of profit last year.
SalesProfit
MAIA Biotechnology vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| MAIA Biotechnology | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads MAIA Biotechnology's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -16 | -20 | -17 | -24 | |
| -16 | -20 | -23 | -22 | |
| -16 | -20 | -23 | -22 | |
| -1.75 | -1.49 | -1.05 | -0.70 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 12 | 8 | 10 | 10 |
| Cash | 11 | 7 | 10 | 9 |
| Total debt | – | – | – | – |
| Total liabilities | 4 | 7 | 7 | 7 |
| 9 | 0 | 4 | 2 | |
| 9 | 13 | 22 | 32 | |
| -146.4% | -3,270.1% | -505.4% | -744.7% | |
| -185.4% | -4,140.8% | -639.8% | -942.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -12 | -13 | -16 | -19 | |
| – | – | – | – | |
| -12 | -13 | -16 | -19 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 3 | 2 | 3 |
Valuation
- –
- –
- –
- 0.0×
- –
- –
- 595.6×
- -29.6%
- -35.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -0.6%
- -1,209.0%
- -3.8%
- -0.2%
- -0.6%
- –
Growth
- –
- –
- −20.0%
- –
- +31.8%
Financial health
- -599.1×
- 0.00
- 0.0%
- –
- 1.66
- 1.66
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 958
Bottom 21%of 888
Bottom 2%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.14 | -0.18 | +22.2% |
| Mar 23, 2026 | -0.08 | -0.13 | +38.5% |
| Nov 7, 2025 | -0.27 | -0.19 | −42.1% |
| Aug 11, 2025 | -0.18 | -0.24 | +25.0% |
| May 9, 2025 | -0.16 | -0.18 | +11.1% |
| Mar 21, 2025 | -0.17 | -0.20 | +15.0% |
| Nov 12, 2024 | -0.11 | -0.32 | +65.6% |
| Aug 9, 2024 | -0.17 | -0.33 | +48.5% |
News
Microsoft (MSFT) Stock May Be 22% Undervalued After Maia 300 UnveilingYahoo Finance · Oct 22, 2026Microsoft Reveals Next-Gen Maia 300 Custom AI Chip For Widespread DeploymentYahoo Finance · Oct 13, 2026Microsoft's AI chief on whether Maia 300 cuts its Nvidia dependence: 'Competition is good'Yahoo Finance · Oct 12, 2026Microsoft unveils the Maia 300, its latest AI chipYahoo Finance · Oct 12, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
15No pass
Benjamin Graham
63Pass
Philip Fisher
30No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
25No pass
Terry Smith
22No pass
Questions about MAIA Biotechnology
Is MAIA Biotechnology a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MAIA Biotechnology AI analysis
What does MAIA Biotechnology do?
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. It is in Biotechnology.
Does MAIA Biotechnology pay a dividend?
No. MAIA Biotechnology does not pay a dividend at the moment.
Is MAIA Biotechnology stock halal?
Yes. MAIA Biotechnology passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has MAIA Biotechnology stock done over the past year?
Down 8.0% over the past twelve months, to $1.03. It traded between $0.87 and $2.95 and is 65.1% below its high.
Who are MAIA Biotechnology's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with MAIA Biotechnology's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.